Literature DB >> 18171934

Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.

Brett Langley1, Melissa A D'Annibale, Kyungsun Suh, Issam Ayoub, Aaron Tolhurst, Birgül Bastan, Lichuan Yang, Brian Ko, Marc Fisher, Sunghee Cho, M Flint Beal, Rajiv R Ratan.   

Abstract

Histone deacetylase (HDAC) inhibitors are currently in human clinical trials as antitumor drugs because of their ability to induce cell dysfunction and death in cancer cells. The toxic effects of HDAC inhibitors are also apparent in cortical neurons in vitro, despite the ability of these agents to induce significant protection in the cells they do not kill. Here we demonstrate that pulse exposure of cortical neurons (2 h) in an in vitro model of oxidative stress results in durable neuroprotection without toxicity. Protection was associated with transcriptional upregulation of the cell cycle inhibitor, p21(waf1/cip1), both in this model and in an in vivo model of permanent ischemia. Transgenic overexpression of p21(waf1/cip1) in neurons can mimic the protective effect of HDAC inhibitors against oxidative stress-induced toxicity, including death induced by glutathione depletion or peroxide addition. The protective effect of p21(waf1/cip1) in the context of oxidative stress appears to be unrelated to its ability to act in the nucleus to inhibit cell cycle progression. However, although p21(waf1/cip1) is sufficient for neuroprotection, it is not necessary for HDAC inhibitor neuroprotection, because these agents can completely protect neurons cultured from p21(waf1/cip1)-null mice. Together these findings demonstrate (1) that pulse inhibition of HDACs in cortical neurons can induce neuroprotection without apparent toxicity; (2) that p21(waf1/cip1) is sufficient but not necessary to mimic the protective effects of HDAC inhibition; and (3) that oxidative stress in this model induces neuronal cell death via cell cycle-independent pathways that can be inhibited by a cytosolic, noncanonical action of p21(waf1/cip1).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171934      PMCID: PMC2577229          DOI: 10.1523/JNEUROSCI.3200-07.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  77 in total

1.  Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.

Authors:  Giuseppe Faraco; Tristano Pancani; Laura Formentini; Paolo Mascagni; Gianluca Fossati; Flavio Leoni; Flavio Moroni; Alberto Chiarugi
Journal:  Mol Pharmacol       Date:  2006-08-31       Impact factor: 4.436

2.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Authors:  V M Richon; T W Sandhoff; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

3.  p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis.

Authors:  R A Steinman; D E Johnson
Journal:  Mol Med       Date:  2000-09       Impact factor: 6.354

4.  Induction of p21 (WAF-1/CIP1) during differentiation.

Authors:  R A Steinman; B Hoffman; A Iro; C Guillouf; D A Liebermann; M E el-Houseini
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

Review 5.  Zinc inhibition of cellular energy production: implications for mitochondria and neurodegeneration.

Authors:  Kirk E Dineley; Tatyana V Votyakova; Ian J Reynolds
Journal:  J Neurochem       Date:  2003-05       Impact factor: 5.372

6.  Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP.

Authors:  A Suzuki; Y Tsutomi; K Akahane; T Araki; M Miura
Journal:  Oncogene       Date:  1998-08-27       Impact factor: 9.867

7.  Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1).

Authors:  Shile Huang; Lili Shu; Michael B Dilling; John Easton; Franklin C Harwood; Hidenori Ichijo; Peter J Houghton
Journal:  Mol Cell       Date:  2003-06       Impact factor: 17.970

8.  Expression patterns of retinoblastoma protein in Parkinson disease.

Authors:  Kelly L Jordan-Sciutto; Robert Dorsey; Elisabeth M Chalovich; Robert R Hammond; Cristian L Achim
Journal:  J Neuropathol Exp Neurol       Date:  2003-01       Impact factor: 3.685

9.  Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1.

Authors:  Minh Dang Nguyen; Mathieu Boudreau; Jasna Kriz; Sebastien Couillard-Després; David R Kaplan; Jean-Pierre Julien
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

10.  p15(INK4b) in HDAC inhibitor-induced growth arrest.

Authors:  Toshiaki Hitomi; Youichirou Matsuzaki; Tomoya Yokota; Yuuki Takaoka; Toshiyuki Sakai
Journal:  FEBS Lett       Date:  2003-11-20       Impact factor: 4.124

View more
  89 in total

1.  Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.

Authors:  Alan P Kozikowski; Sida Shen; Marta Pardo; Maurício T Tavares; Dora Szarics; Veronick Benoy; Chad A Zimprich; Zsófia Kutil; Guiping Zhang; Cyril Bařinka; Matthew B Robers; Ludo Van Den Bosch; James H Eubanks; Richard S Jope
Journal:  ACS Chem Neurosci       Date:  2018-12-14       Impact factor: 4.418

Review 2.  Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

Authors:  Na'ama A Shein; Esther Shohami
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

3.  Development of histone deacetylase inhibitors as therapeutics for neurological disease.

Authors:  Joel M Gottesfeld; Massimo Pandolfo
Journal:  Future Neurol       Date:  2009-11-01

4.  Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.

Authors:  Takuma Uo; Timothy D Veenstra; Richard S Morrison
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

Review 5.  Epigenetics in the nervous system.

Authors:  Yan Jiang; Brett Langley; Farah D Lubin; William Renthal; Marcelo A Wood; Dag H Yasui; Arvind Kumar; Eric J Nestler; Schahram Akbarian; Andrea C Beckel-Mitchener
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

Review 6.  Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury.

Authors:  Selva Baltan; Richard S Morrison; Sean P Murphy
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 7.  Epigenetics and the modulation of neuroinflammation.

Authors:  Gwenn A Garden
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 8.  Epigenetics and the environment: in search of the "toleroasome" vital to execution of ischemic preconditioning.

Authors:  David Brand; Rajiv R Ratan
Journal:  Transl Stroke Res       Date:  2013-01-08       Impact factor: 6.829

Review 9.  The Chemical Biology of Ferroptosis in the Central Nervous System.

Authors:  Rajiv R Ratan
Journal:  Cell Chem Biol       Date:  2020-04-02       Impact factor: 8.116

Review 10.  Multiple roles of HDAC inhibition in neurodegenerative conditions.

Authors:  De-Maw Chuang; Yan Leng; Zoya Marinova; Hyeon-Ju Kim; Chi-Tso Chiu
Journal:  Trends Neurosci       Date:  2009-09-21       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.